viral DNA polymerase Inhibitors
3 drugsAbout viral DNA polymerase
Viral DNA polymerase is an enzyme essential for viral replication, synthesizing new viral DNA strands. Inhibiting this enzyme halts viral propagation, making it a crucial target for antiviral drug development.
Viral DNA polymerase is a validated drug target, evidenced by the clinical efficacy of approved inhibitors. Currently, there is no genetic evidence available directly linking variations in the viral DNA polymerase gene to disease susceptibility or drug response.
Three FDA-approved drugs, including acyclovir, foscavir, and foscarnet sodium, target viral DNA polymerase. All three drugs are small molecules, developed by Sun Pharma Canada, Clinigen Healthcare, and Fresenius Kabi.
Top viral DNA polymerase Drugs
The competitive landscape includes three companies with approved drugs: Sun Pharma Canada, Clinigen Healthcare, and Fresenius Kabi.
The limited number of players suggests a market with relatively low entry barriers.
viral DNA polymerase Drug Modality Landscape
Modalities
Routes of Administration
viral DNA polymerase is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
viral DNA polymerase Clinical Trials 36 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on viral DNA polymerase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 6 | 0 | 2 | 100% |
| Phase 2 | 6 | 5 | 1 | 0 | 83% |
| Phase 3 | 10 | 7 | 1 | 2 | 88% |
| Phase 4 | 12 | 6 | 2 | 4 | 75% |
Top Sponsors
By Modality
viral DNA polymerase Drug Approval Timeline (1991 - 2005)
The first drug was approved in 1991 (Foscavir), and the most recent in 2005 (Foscarnet Sodium), spanning 15 years.
The lack of recent approvals indicates potential saturation or challenges in developing new inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 31 (12 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on viral DNA polymerase. A trial counts if an approved drug acting on viral DNA polymerase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.